Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose radiotherapy + pembrolizumab + paclitaxel albumin + cisplatin as neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma
ChiCTR2500105067Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Complete response rate. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500105067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105067.